VTX 0811
Alternative Names: 617; 61x; 61x anti-PSGL-1 antibody; VTX-0811Latest Information Update: 02 Apr 2024
At a glance
- Originator Verseau Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action P-selectin ligand protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Apr 2024 VTX 0811 is still in preclinical development for Solid tumours in USA (3SBio pipeline, April 2024)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 24 Aug 2022 3SBio obtains IND approval for phase I clinical trial in China, as of March 2022